Barinthus Biotherapeutics plc. Balance Sheet
BRNS|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
Barinthus Biotherapeutics plc. had $98M in total assets and $74M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $70.5M | $110.7M | $142.1M | $194.4M | $214.1M |
| Accounts Receivable | - | - | - | $323.0K | $20.0K |
| Current Assets | $77.8M | $125.7M | $156.9M | $213.0M | $226.8M |
| PP&E (Net) | $3.5M | $7.4M | $11.8M | $8.0M | $1.8M |
| Goodwill | - | - | $12.2M | $12.6M | $12.6M |
| Total Assets | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M |
| Current Liabilities | $10.0M | $15.7M | $12.6M | $12.2M | $11.2M |
| Shareholders' Equity | $74.2M | $130.0M | $186.8M | $242.9M | -$36.9M |